Abstract:ID 92341 Poster Board 545 As one of the most successful set of targets for therapeutic development, GPCRs are activated by diverse array of ligands to induce signaling through multiple distinct pathways, yielding varied biological and physiological responses.The pharmacological concept of biased signaling (functional selectivity) describes the ability of select ligands to preferentially activate one receptor-mediated signaling pathway over others. The development of functionally selective ligands holds significant implications for the development of drugs with fewer side effects. Antibodies (Abs) are useful tools for targeting cell surface proteins; however, developing signaling competent GPCR-targeted Abs remains challenging and is often unsuccessful. Camelid single domain antibodies (or nanobodies, Nbs) have been shown to target epitopes in GPCRs not accessible to conventional Abs. However, it remains difficult to identify Nbs that can directly activate GPCR signaling. We developed a unique methodology in our lab to link PTHR1-binding Nbs with synthetic ligands to provide semi-synthetic conjugates that directly modulate GPCR function to overcome this hurdle. Nb-ligand conjugates were prepared through a combination of enzymatic protein labeling, solid-phase peptide (ligand) synthesis, and chemoselective conjugation chemistry. Unlike conventional approaches that modify the core ligand structure, our strategy involves conjugating the ligand to a nanobody that tethers it to the targeted receptor. The activity of Nb-ligand conjugates were assessed in a series of pharmacological assay, including cAMP production, G-protein dissociation, and β-arrestin translocation assays. The linkage of a weakly active PTHR1 ligand fragment (PTH 1-11 ) to a Nb that bound to PTHR1 extracellular domain caused a substantial enhancement in potency for signaling through the G αs pathway. We also assessed duration of signaling in a cAMP "washout" assay. Results revealed that Nb-peptide conjugates induced prolonged cAMP responses upon ligand washout relative to an analogue of a human PTHR1 drug PTH 1-11 . In contrast, these conjugates displayed a drastically impaired capacity to induce recruitment of β-arrestin to the plasma membrane or to early endosomes or to signal via G αq. These findings mark the Nb-PTH 1-11 conjugates as the most biased agonist of PTHR1 reported to date. We also performed mechanistic studies of the origin of bias, revealing that the Nb-PTH 1-11 conjugates can activate signaling through a mode that involves two receptor protomers (activation in trans ). This mechanism is qualitatively distinct from that of conventional PTHR1 ligands such as PTH 1-34 or PTH 1-11 . The platform described here has the potential to advance our understanding of diseases associated with PTHR1 by enabling selective modulation of individual signaling pathways. Work is underway to expand this platform to generate Nb-based biased agonists of other GPCRs including opioid receptors. Facile generation of biased agonists offers the prospect of probing the utility of pathway-selective signaling for the treatment GPCR-associated diseases. This research was supported by the Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling

Molecular Insights into the Binding Selectivity of a Synthetic Ligand DAAG to Fc Fragment of IgG

Universal mechanism of hormone and allosteric agonist mediated activation of glycoprotein hormone receptors as revealed by structures of follicle stimulating hormone receptor

A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice

The Activation and Differential Signalling of the Growth Hormone Receptor Induced by Pgh or Anti-Idiotypic Monoclonal Antibodies in Primary Rat Hepatocytes

Discovery of the Improved Antagonistic Prolactin Variants by Library Screening.

Differential Intracellular Signalling Properties of the Growth Hormone Receptor Induced by the Activation of an Anti-Ghr Antibody

Synthetic nanobodies as angiotensin receptor blockers.

Allosteric Synthetic Antibody (Allo-Syab) for Improved Cancer Immunotherapy

Bispecific Aptamer Induced Artificial Protein-Pairing: A Strategy for Selective Inhibition of Receptor Function.

Nanobody Tethering Enables Highly Biased Agonism for GPCR Ligands

Receptor selectivity from minimal backbone modification of a polypeptide agonist

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists

Functional Human Antibody CDR Fusions As Long-Acting Therapeutic Endocrine Agonists

Highly biased agonism for GPCR ligands via nanobody tethering

Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping.

Anti-idiotypic Antibody: A New Strategy for the Development of a Growth Hormone Receptor Antagonist

Activation of PTH1 receptor using chimeric peptide templated in situ click reaction of nanobody conjugates

Directed evolution of specific receptor–ligand pairs for use in the creation of gene switches

Synthesis and screening of a cyclic peptide library: discovery of small-molecule ligands against human prolactin receptor.

Directed Evolution of Estrogen Receptor Proteins with Altered Ligand-Binding Specificities.